The AMRF is currently committed to funding research that meets the following criteria:
* investigating potential treatments for advanced melanoma that are:
* related to the human immune system (immunotherapy)
* low cost
* low toxicity
* for all patients
Current Sponsored Research Projects
1) EMOTIV Melanoma Vaccine Study - a clinical trial based at the Royal Adelaide Hospital for patients with Advanced Stage III or IV, non-resectable melanoma. This study is investigating the notion of the 'timing' of vaccine treatment. It is a follow on study from the successful VMCL trial .
2) Immune Cycle Mathematical Analysis - a collaboration between faculties of the University of Adelaide that is delving into proposed cyclical behaviours of the human immune system.
3) Comparison of Current Advanced Melanoma Treatments - a project designed to provide patient friendly insight into the differences between current therapies on offer for advanced melanoma.
4) Long Term Survival Analysis - ongoing surveillance/analysis of the survivors of the 2000-2010 VMCL trial.
5) Timing Effect of IL-2 Therapy of Melanoma in a Mouse Model (completed - awaiting publication)
6) Timing Effect of Higher Dose IL-2 Therapy of Melanoma in a Mouse Model (completed - undergoing statistical analysis)
A Novel Approach
AMRF is endorsing the investigation into 'timing' of treatments based on the following:
Research has repeatedly shown that the immune system plays a crucial role in cancer growth, control or elimination. A small Adelaide based group have been working for many years on a cancer treatment approach where the immune system is ‘boosted’ and toxic effects are greatly reduced. This is being explored using more frequent but less potent treatments.
Combined with that, the identifying of ‘immune cycles’ suggests the timing of treatment may be critical in determining whether the cancer is controlled or permitted to grow. It appears that the successful treatment of cancer may depend on delivering treatment that is accurately timed to match fluctuations in a patients own individual immune 'cycle'. It is understood that each patient’s own repeating ‘immune cycle’ appears to have small ‘windows’ where treatment appears more effective. Treatment during other times of the cycle appears to not be as effective.
This research effort is in line with our Research Vision of developing simple low-cost treatments by "thinking outside the square", rather than pursuing highly complex technology and treatments.
For further information on the immune cycle approach:
* CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?